Chemical structure
Cat.No.
Product Name
CAS no.
Target
YN440392 Glesatinib hydrochloride 1123838-51-6
Glesatinib hydrochloride (MGCD265 hydrochloride) is an orally active, potentMET/SMOdual inhibitor. Glesatinib hydrochloride, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR)...
AMG 337 is an oral, small molecule, ATP-competitive, highly selective inhibitor of the MET receptor with an IC50 of 1 nM.
YN440099 BMS-794833 1174046-72-0
BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2 with IC50 of 1.7 nM/15 nM, also inhibits Ron, Axl and Flt3 with IC50 of <3 nM a prodrug of BMS-817378. Phase 1.
YN440382 SCR-1481B1 1174161-86-4
SCR-1481B1 (c-Met inhibitor 2) is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor.
YN440319 NVP-BVU972 1185763-69-2
NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.
TAS-115 is a potent VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor with IC50s of 30 and 32nM for rVEGFR2 and rMET, respectively.
YN440331 Merestinib 1206799-15-6
LY2801653 is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a dissociation constant (Ki) of 2 nM, a pharmacodynamic residence time (Koff) of 0.00132 min(-1) and t1/2 of 525 min.
YN440332 Merestinib dihydrochloride 1206801-37-7
Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailablec-Metinhibitor (Ki=2nM) with anti-tumor activities. Merestinib dihydrochloride also has potent activity against MST1R (IC50=11nM), FLT3 ...
YN440017 NPS-1034 1221713-92-3
NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.
S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nmol/L.
YN440260 MK-8033 hydrochloride 1283000-43-0
MK8033 Hcl is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1nM Wt c-Met) under investigation as a treatment for cancer.
YN440353 Savolitinib 1313725-88-0
Savolitinib (volitinib, AZD6094, HMPL-504) is a novel, potent, and selective MET inhibitor currently in clinical development in various indications, including PRCC. The IC50 values of this compound for c-Met and p-Met ar...
YN440340 c-Met inhibitor 1 1357072-61-7
c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.
YN440109 Ningetinib 1394820-69-9
Ningetinib is a potent, orally bioavailable inhibitor of tyrosine kinase with IC50 of 6.7 nM, 1.9 nM and <1.0 nM for c-Met, VEGFR2 and Axl, respectively. Ningetinib exhibits antitumor activity.
YN440108 Ningetinib Tosylate 1394820-77-9
Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0nM forc-Met,VEGFR2 and Axl, respectively.
Dihexa, an oligopeptide drug, is an orally active and blood-brain barrier-permeable angiotensin IV analog. Dihexa binds tohepatocyte growth factor (HGF)with high affinity (Kd=65 pM) and potentiates its activity at its receptor,...
YN440025 CEP-40783 1437321-24-8
RXDX-106 (CEP-40783) is an orally-available, potent and selective TAM(TYRO3, AXL, MER)/MET inhibitor displaying low nanomolar biochemical activity and slow (T1/2 >120 min) inhibitor off-rate in peptide phosphorylatio...
YN440215 Bozitinib 1440964-89-5
Bozitinib (PLB-1001) is a highly selective ATP-competitive c-Met inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) selectively inhibits MET-altered tumor cells in preclinical models.
YN440170 Glumetinib 1642581-63-2
Glumetinib (SCC244) is a potent and highly selective c-Met inhibitor with an IC50 of 0.42 ± 0.02 nmol/L. Glumetinib has greater than 2,400-fold selectivity for c-Met over those 312 kinases evaluated, including the c-Met family...
YN440209 TAS-115 mesylate 1688673-09-7
TAS-115 mesylate is a potent VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor, with IC50s of 30 and 32nM for rVEGFR2 and rMET, respectively.
TELL : +86-020-82000279
Add:Room 519, Block F, Guangzhou International Business Incubator, No.3 Lanyue Road, Science Town, Huangpu District, Guangzhou, China.
